1. Home
  2. DAVA vs AVXL Comparison

DAVA vs AVXL Comparison

Compare DAVA & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Endava plc (each representing one)

DAVA

Endava plc (each representing one)

HOLD

Current Price

$2.12

Market Cap

105.2M

Sector

Technology

ML Signal

HOLD

Logo Anavex Life Sciences Corp.

AVXL

Anavex Life Sciences Corp.

BUY

Current Price

$1.37

Market Cap

115.9M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
DAVA
AVXL
Founded
2000
2004
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
105.2M
115.9M
IPO Year
2015
2013

Fundamental Metrics

Financial Performance
Metric
DAVA
AVXL
Price
$2.12
$1.37
Analyst Decision
Hold
Analyst Count
8
0
Target Price
★ $5.39
N/A
AVG Volume (30 Days)
563.2K
★ 1.3M
Earning Date
11-02-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.02
N/A
P/E Ratio
$20.02
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.60
$1.14
52 Week High
$9.88
$8.97

Technical Indicators

Market Signals
Indicator
DAVA
AVXL
Relative Strength Index (RSI) 47.90 27.14
Support Level $1.60 N/A
Resistance Level $3.06 $1.60
Average True Range (ATR) 0.10 0.12
MACD 0.07 0.01
Stochastic Oscillator 74.12 32.59

Price Performance

Historical Comparison
DAVA
AVXL

About DAVA Endava plc (each representing one)

Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

Share on Social Networks: